The effects of neoadjuvant endocrine therapy on expressions of ER, PR and C-erbB-2 in breast cancer patients

VernacularTitle:乳腺癌新辅助内分泌治疗对ER、PR、C-erbB-2表达的影响
Author: Xiaoqing GUAN ; Ji WU ; Shucheng GU ; Yan CHEN ; Jianqiang WU ; Jisheng WU ; Xiaoling JIANG ; Xiaohong SHI
Publication Type:Journal Article
Keywords: Neoadjuvant endocrine therapy; Breast cancer; ER; PR; C-erbB-2
From: Journal of Endocrine Surgery 2009;3(3):158-160
CountryChina
Language:Chinese
Abstract: Objective To explore the effects of preoperative neoadjuvant endocrine therapy on expression and significance of ER, PR, C-erbB-2 in pestmenopause breast cancer patients over 60 years old. Methods 36 patients were treated with endrocrine therapy by oral tamoxifen for 60 ～ 90 days, and the expression of ER, PR and C-erbB-2 was examined before and after the endrocrine therapy. Results In 36 patients the negative expres-sion rate of ER, PR was 16.78% and 11.11% respectively before the endrocrine therapy, compared to 50% and 33.33% after the endrocrine therapy. There was significant difference(P<0.05). The expression of C-erbB-2 was 13.8% and 16.67% before and after the endrocrine therapy, and there was no significant difference between the two figures. Conclusions The neoadjuvant endocrine therapy by tamoxifen alone can down-regulate the ex-pression of ER, PR, and can inhibit tumor growth. Some patients may get partially relieved.